Demonstrates effective fluorescent detection of EGFR L858R mutation, highlighting potential for cost-effective diagnostics.
L858R mutation in patients with nonsmall cell lung cancer, yielding an excellent linear calibration curve (r = 0.9981), recovery rates of 95-110%, and a detection limit of 2.33%. These results demonstrate sensitivity comparable to that of commercial qPCR and next-generation sequencing, while offering advantages in instrument cost, simplicity, and analytical specificity.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: